Hereditary Angioedema Therapeutics Market Report
First published: 20 October 2024 | Last updated: 25 May 2026 | Report Code: hereditary-angioedema-therapeutics
Hereditary Angioedema Therapeutics Market — USD 5.6 billion in 2023, Growing to USD 11.01B by 2033 at 6.8% CAGR
This report provides an in-depth analysis of the Hereditary Angioedema Therapeutics market, focusing on market size, trends, and forecasts from 2023 to 2033. Insights into regional dynamics, competitive landscape, and key industry players are also included.
Key Takeaways
- Global market expands from $5.60 Billion in 2023 to $11.01 Billion in 2033 at a 6.8% CAGR.
- North America is largest regional market, while no single fastest-growing region is stated because regional CAGR differences remain within 0.15 percentage points.
- North America leads regionally, increasing from $2.13 Billion in 2023 to $4.18 Billion in 2033.
- Therapeutic advances such as C1 inhibitors and bradykinin receptor antagonists underpin treatment adoption.
- Top companies active include Takeda Pharmaceuticals, CSL Behring, and Shire (part of Takeda).
- Regional growth reflects rising diagnosis rates, regulatory approvals, and targeted biopharma investments.
Hereditary Angioedema Therapeutics Market Report — Executive Summary
North America remains largest market by forecast-period value, while no single fastest-growing region is stated because top regional growth rates are separated by less than 0.15 percentage points. The market for hereditary angioedema therapies is forecast to progress from $5.60 Billion in 2023 to $11.01 Billion in 2033, reflecting a 6.8% CAGR for 2023 to 2033. Expansion is driven by growing patient recognition, the introduction of novel therapeutics, and focused investment in rare-disease biopharma. Established therapies such as C1 inhibitors and bradykinin receptor antagonists remain central while pipeline innovations and strategic collaborations support long-term momentum. Regional dynamics vary, with North America reaching $4.18 Billion by 2033. Challenges include treatment affordability and access disparities in some markets. The report covers therapy types, routes of administration, indications, end users, and profiles of leading firms to aid stakeholders in planning clinical, commercial, and investment strategies.
Key Growth Drivers
- Increased diagnosis rates and awareness raising among clinicians and patients expand treated populations.
- Development and approval of targeted therapies, including C1 inhibitors and bradykinin receptor antagonists.
- Biopharmaceutical investment and strategic partnerships accelerate pipeline progression for rare-disease treatments.
- Regulatory clearances and reimbursement frameworks in key markets improve therapy access and adoption.
- Expanded delivery options, such as subcutaneous and oral formulations, enhance patient convenience and adherence.
| Metric | Value |
|---|---|
| Study Period | 2023 - 2033 |
| 2023 Market Size | $5.60 Billion |
| CAGR (2023-2033) | 6.8% |
| 2033 Market Size | $11.01 Billion |
| Top Companies | Takeda Pharmaceuticals, CSL Behring, Shire (part of Takeda) |
| Published Date | 20 October 2024 |
| Last Modified Date | 25 May 2026 |
Hereditary Angioedema Therapeutics Market Overview
Customize Hereditary Angioedema Therapeutics Market Report market research report
- ✔ Get in-depth analysis of Hereditary Angioedema Therapeutics market size, growth, and forecasts.
- ✔ Understand Hereditary Angioedema Therapeutics's regional dynamics and industry-specific trends.
- ✔ Identify potential applications, end-user demand, and growth segments in Hereditary Angioedema Therapeutics
What is the Market Size & CAGR of Hereditary Angioedema Therapeutics Market Report market in 2023?
Hereditary Angioedema Therapeutics Industry Analysis
Hereditary Angioedema Therapeutics Market Segmentation and Scope
Tell us your focus area and get a customized research report.
Hereditary Angioedema Therapeutics Market Report Market Analysis Report by Region
Europe Hereditary Angioedema Therapeutics Market Report:
Europe grows from $1.49 Billion in 2023 to $2.93 Billion in 2033. Expansion reflects increasing diagnosis rates, enhanced access to advanced therapeutics, and focused investments in rare-disease clinical programs.Asia Pacific Hereditary Angioedema Therapeutics Market Report:
Asia Pacific grows from $1.12 Billion in 2023 to $2.21 Billion in 2033. Growth drivers include rising clinical awareness, expanding healthcare services, and growing participation in therapeutic research and approvals.North America Hereditary Angioedema Therapeutics Market Report:
North America is largest regional market, rising from $2.13 Billion in 2023 to $4.18 Billion in 2033. Regional momentum is associated with established clinical infrastructure, active adoption of novel therapies, and supportive regulatory and reimbursement environments.South America Hereditary Angioedema Therapeutics Market Report:
Latin America grows from $0.28 Billion in 2023 to $0.55 Billion in 2033. Market development is influenced by gradual improvements in disease recognition, select therapeutic availability, and targeted investment in specialty care.Middle East & Africa Hereditary Angioedema Therapeutics Market Report:
Middle East and Africa grows from $0.58 Billion in 2023 to $1.14 Billion in 2033. Progress is linked to increasing access to specialist treatments, collaborative programs, and incremental enhancements in healthcare infrastructure.Tell us your focus area and get a customized research report.
Research Methodology
Hereditary Angioedema Therapeutics Market Analysis By Therapy Type
In the therapeutics market for hereditary angioedema, C1 inhibitors dominate with a market size of USD 3.82 billion in 2023, projected to increase to USD 7.51 billion by 2033, holding a 68.19% market share. Bradykinin receptor antagonists account for USD 1.49 billion in 2023, expected to grow to USD 2.92 billion by 2033, capturing 26.57% of the market. Other therapies, including Acquired Angioedema treatments, show minor but growing contributions.
Hereditary Angioedema Therapeutics Market Analysis By Route Of Administration
Subcutaneous injections currently dominate the market with a size of USD 3.82 billion in 2023, predicted to rise to USD 7.51 billion by 2033, constituting 68.19% of the administration methods. Intravenous injections follow, valued at USD 1.49 billion in 2023 and estimated to reach USD 2.92 billion by 2033, holding a 26.57% share. Oral administration remains a smaller segment, with a size of USD 0.29 billion in 2023, likely to increase to USD 0.58 billion by 2033.
Hereditary Angioedema Therapeutics Market Analysis By Indication
The market for Hereditary Angioedema is distinguished by type, with Hereditary Angioedema Type I at USD 3.82 billion in 2023 and expected to grow to USD 7.51 billion by 2033. Type II also shows potential, expected to grow from USD 1.49 billion to USD 2.92 billion over the same period. Acquired Angioedema, while smaller, is projected to rise from USD 0.29 billion in 2023 to USD 0.58 billion by 2033.
Hereditary Angioedema Therapeutics Market Analysis By End User
Hospitals are the primary end-users in this market, accounting for USD 3.82 billion in 2023 and likely to reach USD 7.51 billion by 2033, maintaining a 68.19% market share. Clinics represent another significant segment, with a size of USD 1.49 billion in 2023, projected to reach USD 2.92 billion by 2033, which corresponds to a 26.57% share. Home care settings also contribute, with values incrementing from USD 0.29 billion to USD 0.58 billion by 2033.
Hereditary Angioedema Therapeutics Market Trends and Future Forecast
Tell us your focus area and get a customized research report.
Global Market Leaders and Top Companies in Hereditary Angioedema Therapeutics Industry
Takeda Pharmaceuticals:
A leader in WFH (Hereditary Angioedema) therapies, Takeda provides advanced C1 esterase inhibitors and is at the forefront of HAE treatment innovation.CSL Behring:
Known for its extensive product line for plasma-derived therapies and innovative treatments for rare genetic disorders, including various HAE therapeutic options.Shire (part of Takeda):
Shire was pivotal in developing therapies that focus on the unique needs of HAE patients and was acquired by Takeda to enhance its portfolio.We're grateful to work with incredible clients.
FAQs
What is the current market size of the hereditary angioedema therapeutics market?
The market size for 2023 is $5.60 Billion, as stated for the global hereditary angioedema therapeutics market in the provided data.
How big will the market be by 2033?
By 2033 the market is projected to reach $11.01 Billion according to the supplied market forecast figures.
What is CAGR of the market for the forecast period?
The compound annual growth rate for 2023 to 2033 is 6.8% as provided in the input data.
Is there a single fastest Growing region in the Hereditary Angioedema Therapeutics Market Report market?
No single fastest-growing region is stated for the Hereditary Angioedema Therapeutics Market Report market because the top regional implied CAGR values are within 0.15 percentage points of each other, making the ranking too close to call reliably.
Which companies are highlighted as leading players?
Top companies listed include Takeda Pharmaceuticals, CSL Behring, and Shire (part of Takeda) from the provided company list.
What therapy types are included in the market segmentation?
The market segmentation lists C1 inhibitors, bradykinin receptor antagonists, and other therapies as therapy-type categories.
Who are the primary end users in this market?
End-user segments specified are Hospitals, Clinics, and Home Care Settings as listed in the input segment facts.
What are common routes of administration reported?
Reported administration routes include Subcutaneous Injection, Intravenous Injection, and Oral formulations as per the segmentation facts.
How big is the market in Europe according to the data?
The European market is reported to grow from $1.49 Billion in 2023 to $2.93 Billion in 2033 in the provided regional facts.
What drives growth in Asia Pacific?
Asia Pacific growth is tied to increasing diagnosis and therapy uptake, with the market expanding from $1.12 Billion in 2023 to $2.21 Billion in 2033.